

**Literaturverzeichnis zum Titelthema „Neu in der Hämatologie und Onkologie“  
von Professor Dr. Volker Heinemann, Dr. Benedikt Westphalen,  
Professorin Dr. Marion Subklewe und Dr. Veit Bücklein  
Bayerisches Ärzteblatt 1-2/2022, Seite 8 ff.**

1. S3-Leitlinie Kolorektales Karzinom 2019, Langversion 2.1.; Januar 2019 AWMF-Registernummer: 021/007OL
2. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. *J Clin Oncol* 2010;28:466-474.
3. André T, Shiu KK, Kim TW, et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. *N Engl J Med* 2020; 383:2207-2218.
4. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. *Lancet Oncol* 2017;18:1182-1191.
5. Overman MJ, Lonardi S, Wong KYM, et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. *J Clin Oncol* 2018;36:773-779.
6. Subbiah and Cote 2020
7. Wirth, Sherman et al. 2020
8. Subbiah, Hu et al. 2021
9. Westphalen, Bokemeyer et al. 2020
10. Heidt, Knauf et al. 2021
11. Schuster, S. J. et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *New Engl J Med* 380, NEJMoa1804980 (2018).
12. Neelapu, S. S. et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. *New Engl J Medicine* 377, 2531–2544 (2017).
13. Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. *Lancet* 396, 839–852 (2020).
14. Crump, M. et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. *Blood* 130, 1800–1808 (2017).
15. Karschnia, P. et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. *Blood* 133, 2212–2221 (2019).
16. Lee, D. W. et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells. *Biol Blood Marrow Tr 0*, (2018).
17. Rejeski, K. et al. CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma. *Blood* (2021) doi:10.1182/blood.2020010543.